RP G28

Drug Profile

RP G28

Alternative Names: RP-G28

Latest Information Update: 22 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ritter Pharmaceuticals
  • Developer Ritter Pharmaceuticals; University of British Columbia
  • Class Digestion aids; Oligosaccharides
  • Mechanism of Action Bacterial growth stimulants; Carbohydrate metabolism stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Lactose intolerance
  • Preclinical Gastrointestinal disorders

Most Recent Events

  • 12 Mar 2018 Updated efficacy data from a phase IIb/III trial in Lactose intolerance released by Ritter Pharmaceuticals
  • 31 Dec 2017 Ritter Pharmaceuticals initiates enrolment in the phase I pharmacology safety trial for Lactose intolerance in USA in 2017
  • 02 May 2017 Ritter Pharmaceuticals has patent protection for compositions containing RP G28 and methods of using RP G28 in USA and Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top